

# Shucaï Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/334229/publications.pdf>

Version: 2024-02-01

49  
papers

1,168  
citations

516710

16  
h-index

414414

32  
g-index

63  
all docs

63  
docs citations

63  
times ranked

1921  
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and activity of WX-0593 (Iruplinalkib) in patients with ALK- or ROS1-rearranged advanced non-small cell lung cancer: a phase 1 dose-escalation and dose-expansion trial. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 25.	17.1	12
2	Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/ $\beta$ -Catenin activity and cancer stemness. <i>Cancer Letters</i> , 2022, 531, 83-97.	7.2	27
3	CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer. <i>Clinical and Experimental Immunology</i> , 2022, 208, 220-232.	2.6	6
4	Prevalence and management of pain in lung cancer patients in northern China: A multicenter cross-sectional study. <i>Thoracic Cancer</i> , 2022, 13, 1684-1690.	1.9	3
5	A phase II trial of ALK/ROS1 tyrosine kinase inhibitor WX-0593 (iruplinalkib) in ALK-positive and crizotinib-resistant advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9073-9073.	1.6	1
6	Central nervous system efficacy of furmonertinib versus gefitinib in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: Results from FURLONG study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9101-9101.	1.6	3
7	A Modified Method to Isolate Circulating Tumor Cells and Identify by a Panel of Gene Mutations in Lung Cancer. <i>Technology in Cancer Research and Treatment</i> , 2021, 20, 153303382199527.	1.9	1
8	ALK-rearranged squamous cell carcinoma of the lung. <i>Thoracic Cancer</i> , 2021, 12, 1106-1114.	1.9	12
9	Dynamic cfDNA Analysis by NGS in EGFR T790M-Positive Advanced NSCLC Patients Failed to the First-Generation EGFR-TKIs. <i>Frontiers in Oncology</i> , 2021, 11, 643199.	2.8	7
10	Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous non-small-cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21072-e21072.	1.6	3
11	Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21071-e21071.	1.6	0
12	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. <i>Journal of Thoracic Oncology</i> , 2021, 16, 827-839.	1.1	24
13	Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 829-839.	10.7	66
14	IGFBP7 overexpression promotes acquired resistance to AZD9291 in non-small cell lung cancer. <i>Biochemical and Biophysical Research Communications</i> , 2021, 571, 38-45.	2.1	7
15	Possibility of brigatinib-based therapy, or chemotherapy plus anti-angiogenic treatment after resistance of osimertinib harboring EGFR T790M/cis797S mutations in lung adenocarcinoma patients. <i>Cancer Medicine</i> , 2021, 10, 8328-8337.	2.8	9
16	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 45-53.	10.7	105
17	HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib. <i>Frontiers in Oncology</i> , 2020, 10, 1162.	2.8	8
18	Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3162-3171.	7.0	16

#	ARTICLE	IF	CITATIONS
19	Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants. <i>Cancer Medicine</i> , 2020, 9, 3328-3336.	2.8	16
20	The Combination of CD147 and MMP-9 Serum Levels Is Identified as Novel Chemotherapy Response Markers of Advanced Non-Small-Cell Lung Cancer. <i>Disease Markers</i> , 2020, 2020, 1-10.	1.3	8
21	Efficacy and safety of alflutinib (AST2818) in patients with T790M mutation-positive NSCLC: A phase IIb multicenter single-arm study. <i>Journal of Clinical Oncology</i> , 2020, 38, 9602-9602.	1.6	10
22	Establishment of the first international large-scale, genomic screening platform to identify patients with rare oncogene drivers in non-small cell lung cancer (NSCLC) in East Asia. <i>Journal of Clinical Oncology</i> , 2020, 38, 9605-9605.	1.6	2
23	Infiltration of CD8 FOXP3 T cells, CD8 T cells, and FOXP3 T cells in non-small cell lung cancer microenvironment. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 880-888.	0.5	11
24	CD137 ligand feedback upregulates PD-L1 expression on lung cancer via T cell production of IFN- $\gamma$ . <i>Thoracic Cancer</i> , 2019, 10, 2225-2235.	1.9	9
25	Nivolumab-induced Thyroid Dysfunctions in Patients with Previously Treated Non-small Cell Lung Cancer. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2019, 11, 287-291.	3.6	1
26	PD-L1 Expression and Its Regulation in Lung Adenocarcinoma with ALK Translocation. <i>Interdisciplinary Sciences, Computational Life Sciences</i> , 2019, 11, 266-272.	3.6	19
27	Isolation of circulating tumor cells and detection of EGFR mutations in patients with non-small cell lung cancer. <i>Oncology Letters</i> , 2019, 17, 3799-3807.	1.8	15
28	Circulating CD137 <sup>+</sup> CD8 <sup>+</sup> T cells accumulate along with increased functional regulatory T cells and thoracic tumour burden in lung cancer patients. <i>Scandinavian Journal of Immunology</i> , 2019, 89, e12765.	2.7	7
29	Origin of the T790M mutation and its impact on the clinical outcomes of patients with lung adenocarcinoma receiving EGFR-TKIs. <i>Pathology Research and Practice</i> , 2019, 215, 946-951.	2.3	5
30	Glycodelin As A Biomarker Of Advanced Lung Adenocarcinoma Brain Metastases In Patients Treated With EGFR Tyrosine Kinase Inhibitors. <i>Cancer Management and Research</i> , 2019, Volume 11, 9421-9425.	1.9	3
31	Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC. <i>International Journal of Cancer</i> , 2019, 144, 2677-2682.	5.1	34
32	Early detection of lung cancer by using an autoantibody panel in Chinese population. <i>Oncolmmunology</i> , 2018, 7, e1384108.	4.6	54
33	Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). <i>Thoracic Cancer</i> , 2018, 9, 1795-1800.	1.9	3
34	Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1413-1422.	2.5	16
35	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. <i>Nature Communications</i> , 2018, 9, 3114.	12.8	122
36	China experts consensus on the diagnosis and treatment of advanced stage primary lung cancer (2016) <i>Tj ETQq0 Q, Q rgBT /Overlock 10</i>	1.1	34

#	ARTICLE	IF	CITATIONS
37	Mechanisms of resistance to irreversible epidermal growth factor receptor tyrosine kinase inhibitors and therapeutic strategies in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 90557-90578.	1.8	34
38	An updated analysis of ICOGEN to demonstrate utility of a blood-based proteomic test to predict outcomes in EGFR TKI treated patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e20655-e20655.	1.6	0
39	Sequential measurements of serum matrix metalloproteinase 9 to monitor chemotherapy responses in patients with advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 3299.	2.0	4
40	Clinicopathological characteristics and outcomes ofROS1-rearranged patients with lung adenocarcinoma withoutEGFR,KRASmutations andALKrearrangements. <i>Thoracic Cancer</i> , 2015, 6, 413-420.	1.9	25
41	Expression and clinical significance of aminopeptidase N/CD13 in non-small cell lung cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2015, 11, 223.	0.9	37
42	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <i>PLoS ONE</i> , 2015, 10, e0142500.	2.5	14
43	Molecular Epidemiology of EGFR Mutations in Asian Patients with Advanced Non-Small-Cell Lung Cancer of Adenocarcinoma Histology “ Mainland China Subset Analysis of the PIONEER study. <i>PLoS ONE</i> , 2015, 10, e0143515.	2.5	143
44	ALK-rearranged squamous cell lung cancer: a case report. <i>International Journal of Clinical and Experimental Pathology</i> , 2015, 8, 2195-8.	0.5	11
45	Clinical Characteristics and Outcomes of Patients with Primary Lung Adenocarcinoma Harboring ALK Rearrangements Detected by FISH, IHC, and RT-PCR. <i>PLoS ONE</i> , 2014, 9, e101551.	2.5	53
46	A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2014, 86, 207-212.	2.0	47
47	Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with <i>EGFR</i> mutation-positive advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 7520-7520.	1.6	40
48	Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7559-7559.	1.6	4
49	Detection of EGFR and KRAS somatic mutations in tumor tissue and peripheral blood by a liquidchip technology for patients with advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18142-e18142.	1.6	1